Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26802 | 0.87 | ALDH1A1 (0.48) | LMNATSHRALDH1A1AOC3NPC1 | |
| SCHEMBL8857306 | 0.84 | TSHR (0.43) | LMNATSHRALDH1A1AOC3NPC1 | |
| SCHEMBL24043967 | 0.82 | CARM1 (0.43) | LMNATSHRALDH1A1CNR2AOC3 | |
| SCHEMBL14141343 | 0.82 | CARM1 (0.51) | LMNATSHRALDH1A1NPC1RAB9A | |
| SCHEMBL7272839 | 0.81 | HDAC6 (0.44) | TSHRALDH1A1 | |
| SCHEMBL7397101 | 0.80 | AOC3 (0.53) | AOC3NPC1RAB9A | |
| SCHEMBL16708762 | 0.80 | USP2 (0.42) | LMNATSHRALDH1A1MAPK1KDM4E | |
| SCHEMBL5013428 | 0.80 | KCNH2 (0.46) | CNR2 | |
| SCHEMBL8415458 | 0.79 | TSHR (0.48) | LMNATSHRALDH1A1CNR2AOC3 | |
| SCHEMBL7087904 | 0.79 | TSHR (0.41) | LMNATSHRALDH1A1AOC3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107827817-B | Method for synthesizing formamide derivative through molybdenum catalytic formylation reaction | 湘潭大学 | 2020-03-13 | — | — | CN | claimed |
| CN-107827816-B | Method for synthesizing formamide derivative through graphene oxide catalytic formylation reaction | 湘潭大学 | 2020-01-10 | — | — | CN | claimed |
| CN-107892670-B | Method for synthesizing formamide derivative through cobalt-catalyzed formylation reaction | 湘潭大学 | 2019-12-13 | — | — | CN | claimed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | claimed |
| US-7951816-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | claimed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | claimed |
| CN-107827817-B | Method for synthesizing formamide derivative through molybdenum catalytic formylation reaction | 湘潭大学 | 2020-03-13 | — | — | CN | disclosed |
| CN-107827816-B | Method for synthesizing formamide derivative through graphene oxide catalytic formylation reaction | 湘潭大学 | 2020-01-10 | — | — | CN | disclosed |
| CN-107892670-B | Method for synthesizing formamide derivative through cobalt-catalyzed formylation reaction | 湘潭大学 | 2019-12-13 | — | — | CN | disclosed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| CN-1091288-A | The oxytocin antagonist | OTSUKA PHARMA CO LTD (JP) | 1994-08-31 | — | — | CN | disclosed |
| EP-0171217-B1 | FUSED-RING HETEROCYCLIC COMPOUNDS A PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | disclosed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | LMNA 635/4885TSHR 2802/4885ALDH1A1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.